STAMPEDE: Abiraterone Slowed Progression of Advanced Prostate Cancer

Abiraterone at the start of ADT for men with metastatic prostate cancer significantly improved overall survival and failure-free survival, with manageable toxicity.

Source: CancerNetwork - June 3, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Prostate Cancer News Source Type: news